NasdaqGS:JAZZPharmaceuticals
Jazz Pharmaceuticals (JAZZ) Q1 EPS Rebound Tests Bearish Margin Narratives
Jazz Pharmaceuticals (JAZZ) opened 2026 with Q1 revenue of US$1.1 billion and basic EPS of US$4.74, setting a clear marker against last year’s volatile run of quarterly results. Over recent quarters the company has seen revenue move from US$897.8 million in Q1 2025 to US$1.09 billion in Q4 2024 and then to US$1.07 billion in Q4 2025. Basic EPS has shifted from a loss of US$1.52 per share in Q1 2025 to US$3.16 in Q4 2024 and US$3.33 in Q4 2025, leaving investors focused on how much of the...